Cardiovascular disease is the leading cause of death worldwide. It is no surprise that the question of how to support heart health concerns so many people. Omega-3 fatty acids — particularly EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) from marine sources — are among the most intensively researched nutrients in cardiology. In this article you will find out what current data really demonstrates — precisely, without exaggerated promises, but without downplaying the essentials either.
TL;DR — Key points
- The EFSA has approved 250 mg EPA+DHA daily as the minimum dose for normal cardiac function (EU Regulation No. 432/2012).
- The REDUCE-IT study (8,179 patients, 4.9 years) showed a 25% reduction in serious cardiovascular events with 4 g/day of pure EPA versus placebo.
- A meta-analysis of 127,477 participants confirmed a dose-response relationship: each additional 1 g/day of omega-3 significantly reduces the risk of myocardial infarction.
- EPA and DHA act through several mechanisms: triglyceride reduction, inflammation modulation, blood pressure effects and antiarrhythmic properties.
- People with a low omega-3 index (below 4%) and elevated triglyceride levels benefit most from supplementation.
The EFSA health claim: normal cardiac function
The EFSA, following extensive evidence review, approved the following health claim for omega-3 fatty acids: EPA and DHA contribute to normal cardiac function. This claim applies from a minimum dose of 250 mg EPA+DHA per day. This is approximately the amount found in one portion of oily fish (e.g. salmon or mackerel, 100–150 g).
EFSA Health Claim: cardiac function
According to the EFSA, EPA and DHA contribute to normal cardiac function. Approved minimum dose: 250 mg EPA+DHA per day. Foods or dietary supplements may carry this claim if they contain at least 250 mg EPA+DHA per daily serving. (EU Regulation No. 432/2012)
It is important to understand: a health claim describes a physiologically normal function — it is not a therapeutic claim. 'Normal cardiac function' means that sufficient EPA and DHA should be present for the heart to perform its normal tasks. Those who eat little fish can meet their needs with high-quality fish oil or algae oil supplements.
The REDUCE-IT study: a milestone in cardiology
Few omega-3 studies have attracted as much attention in recent years as the REDUCE-IT trial (Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial). This double-blind, randomised, placebo-controlled study was published in 2019 in the New England Journal of Medicine and is one of the most cited intervention trials in modern cardiology.
Study design and participants
REDUCE-IT studied 8,179 patients over a median period of 4.9 years. Inclusion criteria: all participants had elevated triglyceride levels (135–499 mg/dL) despite statin therapy and either established cardiovascular disease or at least one additional risk factor (e.g. diabetes mellitus plus at least one additional risk factor). Half the patients received 4 g daily of icosapent ethyl (highly purified EPA ethyl ester), the other half a placebo (mineral oil).
Results: 25% reduction in cardiovascular endpoints
The result was remarkable: the treatment group showed a 25% reduction in the primary endpoint (combined cardiovascular endpoint) versus placebo (Hazard Ratio 0.75; 95% CI 0.68–0.83; p < 0.001). The primary endpoint included non-fatal myocardial infarction, non-fatal stroke, cardiovascular death, coronary revascularisation and unstable angina pectoris.
Further important results from REDUCE-IT:
- Cardiovascular death: reduced from 5.2% (placebo) to 4.3% (EPA)
- Non-fatal myocardial infarction: significantly reduced (HR 0.69)
- Stroke: also significantly reduced (HR 0.72)
- Coronary revascularisation: HR 0.65
REDUCE-IT: cardiovascular endpoints with icosapent ethyl (4 g/day EPA)
Double-blind, randomised trial with 8,179 patients over 4.9 years. Administration of 4 g/day of pure EPA showed a 25% reduction in primary cardiovascular endpoints (HR 0.75; 95% CI 0.68–0.83; p < 0.001). Cardiovascular mortality fell from 5.2% to 4.3%. NNT (Number Needed to Treat) over 4.9 years: 21 patients.
REDUCE-IT has triggered an important debate: part of the scientific community discusses whether the mineral oil placebo in the control group may have had negative effects, thereby artificially widening the difference between groups. This point has not been definitively resolved scientifically.
The FDA approved icosapent ethyl (Vascepa) based on REDUCE-IT as the first omega-3 supplement for cardiovascular event risk reduction.
Meta-analysis of 127,477 participants: dose-response relationship
While REDUCE-IT studied a high-risk population, a large-scale meta-analysis by Hu et al. (JAHA 2019) provides a broader picture. The authors — Yu Hu, Frank B. Hu and JoAnn E. Manson from the Harvard T.H. Chan School of Public Health — analysed 13 randomised controlled trials with a total of 127,477 participants.
Central result: dose-response relationship
The meta-analysis found that marine omega-3 supplementation significantly reduced the risk of several cardiovascular endpoints:
- Myocardial infarction: significant risk reduction demonstrated
- Coronary heart death: significantly reduced
- Total CVD events: significantly reduced
- Stroke: not statistically significant in the overall group
Particularly relevant: the analysis showed a dose-response relationship — higher omega-3 doses were associated with greater risk reduction. An increase in omega-3 dose of 1 g/day was associated with a significant reduction in myocardial infarction risk.
Cardiovascular risk: 13 randomised trials with 127,477 participants
Marine omega-3 supplementation reduced the risk of myocardial infarction (RR 0.92; 95% CI 0.86–0.98), coronary heart death (RR 0.92; 95% CI 0.86–0.98) and total CVD events significantly. A dose-response relationship was observed: higher omega-3 doses showed greater risk reduction. Per 1 g/day additional omega-3: significantly reduced myocardial infarction risk.
Mechanisms: how does omega-3 act on the cardiovascular system?
The cardiovascular effects of EPA and DHA are attributed to various mechanisms investigated in numerous experimental and clinical studies:
Triglyceride-lowering effect
EPA and DHA inhibit hepatic VLDL synthesis and increase beta-oxidation of fatty acids in the liver. At doses from 2 g/day EPA+DHA, studies observe significant triglyceride reductions. At 4 g/day, studies show reductions of over 30% (more in the article Lowering triglycerides with omega-3).
Inflammation modulation
EPA and DHA serve as precursors for anti-inflammatory lipid mediators (resolvins, protectins, maresins). They also displace arachidonic acid (AA) from cell membranes, reducing the formation of pro-inflammatory prostaglandins and leukotrienes. Chronic inflammation is a key factor in the formation and progression of atherosclerotic plaques.
Blood pressure effects
EPA and DHA can exert vasodilatory effects and improve endothelial function. Meta-analyses show that higher doses can significantly lower blood pressure — especially in people with hypertension (more in the article Omega-3 for high blood pressure).
Antiarrhythmic properties
EPA and DHA influence cardiac ion channels (particularly sodium channels) and can support the electrical stability of the heart. This mechanism is discussed as one of the possible explanations for the reduction in cardiovascular mortality in REDUCE-IT.
Effects on platelets and thrombosis risk
EPA and DHA can modulate platelet aggregation and reduce the formation of thrombogenic thromboxanes (thromboxane A2), while favouring the formation of prostacyclin (vasodilatory, antiaggregatory). This can theoretically influence the risk of thrombotic events.
Overview: omega-3 dosages and cardiovascular study effects
| Dosage EPA+DHA/day | EFSA status | Study results | Note |
|---|---|---|---|
| 250 mg | Health claim | Normal cardiac function | EFSA-approved minimum value |
| 500–1,000 mg | No EFSA claim | Initial cardiovascular effects in observational studies | Recommendation for general population (DGE, AHA) |
| 2,000 mg | Health claim | Normal triglyceride levels; significant CVD risk effects in meta-analyses | EFSA claim triglycerides from 2,000 mg |
| 3,000 mg | Health claim | Normal blood pressure regulation; stronger triglyceride effects | EFSA claim blood pressure from 3,000 mg |
| 4,000 mg (EPA) | FDA-approved | REDUCE-IT: 25% reduction in CV endpoints; >30% triglyceride reduction | Only under medical supervision in high-risk patients |
Who benefits most — and what do current guidelines say?
Not everyone benefits equally from omega-3. The evidence is strongest for:
People with elevated triglyceride levels
In hypertriglyceridaemia, omega-3 fatty acids show the most consistent and strongest effects. The EFSA health claim for triglyceride levels starts at 2 g/day EPA+DHA; at 4 g/day, reductions of over 30% are documented.
People with existing cardiovascular risk
REDUCE-IT and related studies were conducted in high-risk patients. The higher the baseline risk, the greater the absolute benefit of an intervention in studies. People with low baseline cardiovascular risk show, as expected, smaller absolute risk reductions in studies.
People with a low baseline omega-3 status
The omega-3 index (proportion of EPA+DHA in erythrocyte fatty acids) is considered a relevant biomarker. A low index below 4% is associated with increased cardiovascular risk. People with low fish consumption often have low baseline values and may benefit particularly from supplementation.
Guidelines position
The American Heart Association (AHA) recommends:
- Oily fish twice per week for the general population
- Omega-3 supplementation for patients with coronary heart disease
- Prescription omega-3 supplements (4 g/day) for patients with severe hypertriglyceridaemia
Frequently asked questions
Are 250 mg of EPA+DHA per day sufficient for the heart?
The EFSA has set 250 mg EPA+DHA as the minimum dose for the health claim 'contributes to normal cardiac function'. This amount is sufficient to fulfil the EFSA claim. Clinical intervention trials that showed stronger cardiovascular effects (e.g. REDUCE-IT) used considerably higher doses (up to 4 g/day EPA). The optimal dose depends on the individual risk profile — it is best to discuss this with your doctor.
Is omega-3 a substitute for cholesterol-lowering medications?
No. Omega-3 fatty acids have no relevant effect on LDL cholesterol and are not a substitute for statins or other lipid-lowering medications. They complement drug therapy — as in REDUCE-IT, where all participants were already taking statins. Any change to ongoing medication must only be made in consultation with a doctor.
What omega-3 dose was used in REDUCE-IT?
In REDUCE-IT, pure EPA (icosapent ethyl) was used at a dose of 4 g per day — split into two doses of 2 g in the morning and evening. This was highly purified EPA without any DHA, in ethyl ester form. This dose is considerably higher than typical everyday supplementation and should only be taken under medical supervision.
Does REDUCE-IT apply to people without heart disease?
REDUCE-IT studied exclusively high-risk patients (established CVD or diabetes plus additional risk factors, elevated triglycerides despite statins). The results cannot simply be extrapolated to the general population. For primary prevention in otherwise healthy people, the EFSA recommends the basic claim from 250 mg EPA+DHA daily to support normal cardiac function.
Is there an omega-3 test to know one's own status?
Yes. The so-called omega-3 index measures the proportion of EPA+DHA in red blood cells (erythrocyte membranes) and is considered a valid long-term biomarker. Values below 4% are considered low and associated with increased cardiovascular risk; values above 8% are considered optimal. Some providers (e.g. OmegaQuant, Zinzino BalanceTest) offer home test kits. Your doctor can also order the test through a laboratory.
Important note on bleeding time
High-dose omega-3 supplements (from approximately 3 g/day) can prolong bleeding time. If you take anticoagulants (warfarin, direct oral anticoagulants) or have planned surgery, be sure to inform your doctor. The FDA daily maximum dose for dietary supplements is 3 g/day; higher doses should only be taken on medical prescription.
Related articles
The topic of cardiovascular health is closely linked to two other specific effects of omega-3 that have their own EFSA health claims:
- Omega-3 for high blood pressure — EFSA health claim from 3,000 mg/day and meta-analysis of 70 RCTs
- Lowering triglycerides with omega-3 — AHA Science Advisory and EFSA health claim from 2,000 mg/day
- All health effects of omega-3 — overview of all areas of effect
Medical disclaimer
This article is for general informational purposes and does not replace medical advice. All health claims are based on EFSA-approved health claims and published studies. Dietary supplements are not a substitute for a balanced diet and healthy lifestyle. People with cardiovascular disease or existing medication plans should discuss any supplementation with their doctor.